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We report short and efficient scalable syntheses of enantiomerically pure (3R,4S)-3-(hydroxymethyl4-
(hydroxyethyl))-piperidine and 1-hydroxymethyl-octahydro-1H-pyrano[3,4-c]pyridine scaffolds. The
alkaloid core was readily synthesized from naturally occurring quinine and can serve as a valued starting
point for drug-discovery. Cleavage of a terminal 1,2-diol and acid catalysed epoxide opening cyclization
are the key steps involved. A number of members of a projected small-molecular library is synthesized for
each scaffold.
 2017 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Despite numerous advances in the field of therapeutics our abil-
ity to treat diseases remains limited. On the one hand, the develop-
ment of new drug candidates is hampered by the high cost and low
rate of target-lead discovery.1 On the other hand, structural diver-
sity in small molecular libraries is essential to populate new chem-
ical space and to uncover bioactive molecules with potential
pharmacological properties. Until recently the chemical library
designs for high throughput screening (HTS) was mostly limited
to flat molecules with high sp2-carbon content. With increase in
medicinal chemists’ ability to track physical properties of mole-
cules has rightly highlighted the need of more three dimensional
sp3-carbon rich molecular scaffolds for improving therapeutic
efficiency.3
The joint European compound library (JECL) is an unique asset
developed by European Lead Factory (ELF), which is a public-pri-
vate initiative of European Union aimed to accelerate drug devel-
opment. The aim here is to offer novel three-dimensional lead
compounds to probe novel drug targets, including the emerging
ones such as protein-protein interactions. This is expected that
JECL will enable the medicinal chemistry community to discovertrue potential of sp3-carbon rich heterocyclic scaffolds in biologi-
cally-relevant chemical space.4,5
Functionalized piperidines are frequently studied aza-heterocy-
cles, as they are found in many natural products and synthetic
drugs.6 ()Epimythrine A, () pinidinol B and (+)Alkaloid 241D C
are representative examples of bioactive piperidines (Fig. 1).7
Owing to their pharmacological properties a number of routes for
the synthesis of multifunctional piperidines, including enantiose-
lective syntheses are reported. Frequently used protocols involve
cycloaddition reactions, reductive cyclization, ring closing
metathesis, metal catalysed reactions, hydroamination, multicom-
ponent reactions and hydrogenation of pyridines.8 Taking into
account their compact structure and interesting properties, it is
remarkable that synthetic cis-3,4-disubstituted piperidines are sel-
dom evaluated for bioactivity.9 Octahydropyrano[3,4-c]pyridines
are part of many alkaloid natural products including ()Ajmalicine
D and ()Tetrahydroalstonine E among others (Fig. 1).10 Octahy-
dropyrano[3,4-c]pyridines, perhaps due to a relatively complex
synthetic access to these, remain rarely studied heterocycles in
synthetic and medicinal chemistry despite having an 1,3-amino
alcohol and a piperidine moieties that are present in many natural
products.11
In this paper, we will present a synthesis route to obtain novel
molecular libraries of sp3-rich molecules and natural product-like
scaffolds to enrich the JECL. These libraries will be screened at
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drug discovery programs. Here, we discuss the use of quinine as a
readily available chiral starting compound for the development of
two molecular libraries, namely (3R,4S)-3-(hydroxymethyl4-
(hydroxyethyl))-piperidine 8 and 1-hydroxymethyl-octahydro-
1H-pyrano[3,4-c]pyridines 15, 16 respectively.Table 1
Specific examples from piperidine based library that have been prepared in this study.
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Key intermediate 4 that was required for the preparation of
both scaffolds was efficiently synthesized from naturally occurring
cinchona alkaloid quinine (1) using literature protocols.12,13 Oppe-
nauer–Woodward oxidation of quinine 1 was followed by oxida-
tive degradation to yield piperidine core 2 in 80% yield. LiAlH4
reduction of the ester function followed by protection of the sec-
ondary amine with Boc-group yielded alcohol 3. Subsequently,
the alcohol was protected by treatment with TBS-Cl in presence
of imidazole. Next, the hydroxylation of 3 with potassium
osmate/N-methylmorpholine-N-oxide in aqueous acetone yielded
key intermediate 4 in 92% yield as 1:1 mixture of diastereomeric
diols (Scheme 1).N
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Scheme 1. Synthesis of key diol intermediate 4.thus obtained, was reduced with sodium borohydride to produce
alcohol 5 in good yield (Scheme 2). The free hydroxyl group in 5
was then used as first diversification point and was either con-
verted into an ether by treatment with ethyl bromide or trans-
formed into a carbamate by sequential treatment with
triphosgene and pyrrolidine. Upon cleavage of the silyl ether
(TBS) alcohols 6a and 6b were obtained. The free hydroxyl group
in 6 was converted into either benzyl ether or t-butyl carbamate
(7) by treatment either with benzyl bromide and sodium hydride
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overnight and the free amine as a second diversification point
was converted into diverse array of functional groups such as an
amide (8a, 8d, 8e, 8f, 8h–8n), an urea (8c) carbamate (8g) and
sulfone amide (8b) by reaction with an acid chloride, isocyanate,
chloroformate and sulfonyl chloride respectively in 51–82%
isolated yields. A number of acid chlorides including with function-
alized aliphatic (8h, 8k) and heteroaromatic (8e, 8i) substitution
reacted to deliver the amide products. (Table 1).2.2. Synthesis and diversification of octahydropyrano[3,4-c]pyridine
scaffolds
Next, we decided to use readily available intermediate 3 to
synthesize octahydro-pyrano[3,4-c]pyridine core by iodine
mediated cyclization (Scheme 3). However, all reactions we tried
using various bases such as anhydrous or aqueous NaHCO3,
K2CO3, NaOH and solvents CH2Cl2, CH3CN, EtOAc, DMF resulted in
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sluggish reaction (Scheme 3). To overcome these problems, we
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13/14 with several acid chlorides, chloroformates, sulfonyl chlo-
rides and isocyanates (Scheme 4). All the reactions worked well
to yield corresponding amides (15a, 15e, 16c), carbamates (15c,
15d, 15f, 15h, 16a, 16d), sulfonamides (15b, 15i, 16b, 16f) or ureas
(15g, 16e) in 75–90% yields (Table 2).3. Conclusions
In conclusion, we have successfully developed an efficient syn-
thesis of the sp3-rich scaffolds 3,4-disubstituted chiral piperidines
and octahydropyrano[3,4-c]pyridines for the development of
focused compound libraries for drug discovery. Use of quinine, a
readily available starting compound, and robust chemistry
involved should make this protocol attractive for large library syn-
thesis for development of new leads and drug candidates.4. Experimental section
4.1. General information
Commercially available reagents were used throughout without
further purification unless otherwise stated. Dichloromethane
(DCM), di-methylformamide (DMF) tetrahydrofuran (THF) and
acetonitrile (ACN) were stored over 4 Å molecular sieves. All reac-
tions were carried out under nitrogen or argon atmosphere unless
mentioned otherwise. Thin layer chromatography was carried out
using aluminum backed plates coated with silica gel. The plates
were visualized under UV light at 254 nm and/or by sulphuric acid
in methanol or potassium permanganate stains. Flash column
chromatography was carried out using silica gel (0.040–0.063
mm) with eluents specified. Purification by reverse phase column
chromatography was performed using Reveleris, 12 g acidic col-
umns. 1H and 13C NMR spectra were recorded on Bruker DMX-
400 and AV-400 instruments (1H frequencies 400 MHz, corre-
sponding 13C frequencies are 101 MHz respectively). Chemical
shifts are quoted in parts per million (ppm). Coupling constants
(J) values are recorded in Hz. The spectral data of known com-
pounds are in accordance with literature data. High resolution
mass spectra were recorded by direct injection (2 lL of a 2 lM
solution in water/acetonitrile; 50/50; v/v and 0.1% formic acid)
on a mass spectrometer (Thermo Finnigan LTQ Orbitrap) equipped
with an electrospray ion source in positive mode (source voltage
3.5 kV, sheath gas flow 10, capillary temperature 250 C) with res-
olution R = 60,000 at m/z 400 (mass range m/z = 150–2000) and
dioctylpthalate (m/z = 391.2842) as a ‘‘lock mass”. The high resolu-
tion mass spectrometer was calibrated prior to measurements with
a calibration mixture (Thermo Finnigan).4.2. Synthetic procedures
4.2.1. tert-Butyl 2-((3R,4S)-3-vinylpiperidin-4-yl)acetate (2)
Quinine (1) (67 g, 206 mmol) was dissolved in 400 mL of dry
toluene. To this mixture benzophenone (75 g, 412 mmol) and
KOt-Bu (58 g, 517 mmol) were added and the resulting mixture
was refluxed overnight. The reaction mixture was cooled down
to room temperature and quenched with 2 M HCl (275 mL) solu-
tion. The organic layer was extracted with 2 M HCl (100 mL) solu-
tion. The water layers were combined and the pH was adjusted to
14 by the addition of 35% NH4OH solution. The resulting mixture
was extracted three times with 300 mL of dichloromethane. The
organic layers were combined, washed with brine, dried with Na2-
SO4 and the product was concentrated and directly used in the
next step.Through a solvent mixture THF/t-BuOH (4:1, 750 mL) oxygen
was bubbled for a period of 15 min. Then KOt-Bu (58 g, 517 mmol
was added and the mixture was cooled to 0 C. Purging of the mix-
ture with oxygen was continued for another 15 min. Then crude
ketone was added over a period of 10 min (this can be done by
making a solution of the crude in a small volume of THF). The
resulting red mixture was warmed to room temperature and purg-
ing of oxygen was continued for 1.5 h. The reaction was quenched
with AcOH (60 mL) and the volatiles were removed under reduced
pressure, keeping the water bath below 50 C. The crude product
was then dissolved in water (300 mL) and the pH was adjusted
to 14 by the addition of 35% NH4OH solution. The mixture was then
extracted with Et2O (4x50 mL). The organic layers were combined,
washed two times with brine, dried over Na2SO4 and the product
was concentrated to give piperidine 2 (38 g, 169 mmol, 80% over
2 steps). All analytical data was in accordance to those reported
in literature.1
4.2.2. (3R,4S)-tert-Butyl 4-(2-hydroxyethyl)-3-vinylpiperidine-1-
carboxylate (3)
A mixture of lithium aluminum hydride in THF (2.4 M,
266 mmol, 111 mL) and tetrahydrofuran (dry) (150 mL) was cooled
to 0 C. A solution of tert-butyl 2-((3R, 4S)-3-vinylpiperidin-4-yl)
acetate 2 (50 g, 222 mmol) in tetrahydrofuran (100 mL) was added
dropwise. Subsequently, the temperature was raised to room tem-
perature and the reaction mixture was stirred for 1 h. The reaction
mixture was cooled using an ice/water bath. The reaction was
quenched by dropwise addition of H2O (13 mL; 1.3 mL/g LiAlH4)
followed by dropwise addition of aq. 4 M NaOH (13 mL; 1.3 mL/g
LiAlH4) and addition of H2O (26 mL; 2.6 mL/g LiAlH4). The resulting
mixture was stirred vigorously for 15 min. Filtration was followed
by washing the residue with Et2O (3  100 mL). The volatiles were
removed under reduced pressure to get 2-((3R,4S)-3-vinylpiperi-
din-4-yl)ethanol (33.34 g, 97%) as an oil.
The crude alcohol (33.2 g, 214 mmol) was dissolved in metha-
nol (200 mL) and the solution was stirred at 0 C. Di-tert-
butyldicarbonate (51.3 g, 235 mmol) was added in portions fol-
lowed by addition of NaOH 9.41 g, 235 mmol). The resulting mix-
ture was stirred at room temperature overnight. The crude
material was concentrated and dissolved in EtOAc (600 mL) and
ice cold water (120 mL) was added. The two layers were separated
and the water layer was extracted with EtOAc (100 mL). The
organic layers were combined, washed with brine and dried with
Na2SO4 and concentrated under reduced pressure to give (3R,4S)-
tert-butyl 4-(2-hydroxyethyl)-3-vinylpiperidine-1-carboxylate 3
(45.08 g, 91%) as a sticky colourless oil. All analytical data was in
accordance to those reported in literature.2
4.2.3. (3R,4S)-tert-Butyl-4-(2-((tert-butyldimethylsilyl)oxy)ethyl)-3-
(-1,2-dihydroxyethyl) piperidine-1-carboxylate (4)
Alcohol 3 (45.08 g, 161 mmol) and imidazole (16.41 g,
241 mmol) were dissolved in dry dichloromethane (225 mL). The
reaction mixture was stirred in a water bath at 10 C and TBSCl
(27.8 g, 185 mmol) was added in 2.0 g portions over 20 min. The
reaction mixture was stirred for 1 h at this point water (150 mL)
was added and the layers were separated. The water layer was
extracted with dichloromethane (2  50 mL). The organic layers
were combined and dried with Na2SO4 concentrated under
reduced pressure and the crude product was purified by column
chromatography (heptane/EtOAc, 15/1 & 9/1) to get (3R,4S)-tert-
butyl 4-(2-((tert-butyldimethylsilyl)oxy)ethyl)-3-vinylpiperidine-
1-carboxylate (54.8 g, 92%)) as an oil.
The above prepared olefin (49.2 g, 133 mmol) was dissolved in a
1:1 mixture of acetone/water (400 mL). To this mixture N-methyl-
morpholine-N-oxide (18.8 g, 160 mmol) and potassium osmate
dihydrate (1.47 g, 4 mmol) were added and the reaction mixture
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was added and the resulting mixture was stirred for an additional
2 h. Addition of brine (225 mL) and EtOAc (300 mL) resulted in a
two-phase system with a lot of voluminous brown solid. The
phases were filtered over a cotton plug and separated, the water
phase was extracted with EtOAc (2  100 mL). The organic layers
were combined, washed with brine, dried with Na2SO4 and the
product was concentrated to give diastereomeric mixture of diols
(3R,4S)-tert-butyl 4-(2-((tert-butyldimethylsilyl)oxy)ethyl)-3-(-
1,2-dihydroxyethyl)piperidine-1-carboxylate 4 as yellow oil quan-
titatively (53.7 g). 1H NMR (400 MHz, CDCl3) d 3.81–3.66 (m, 4H),
3.66–3.47 (m, 10H), 3.44–3.27 (m, 3H), 3.25–2.98 (m, 3H), 2.91–
2.66 (m, 2H), 2.13–2.02 (s, 1H), 1.91–1.89 (m, 1H), 1.78–1.60 (m,
4H), 1.60–1.43 (m, 8H), 1.41 (s, 9H), 1.39 (s, 9H), 0.85(s, 9H), 0.83
(s, 9H), 0.03 (s, 6H), 0.05 (s, 6H). 13C NMR (101 MHz, CDCl3) d
155.3, 154.94, 79.7, 79.6, 70.9, 70.1, 64.9, 64.7, 62.6, 61.0, 43.1,
41.6, 41.4, 40.1, 29.2, 28.3, 28.3, 28.1, 25.9, 25.8, 18.3, 18.2, 5.4,
5.5. ESI-HRMS [C20H41NO5Si+H]+: 404.28276 found, 404.28268
calculated.4.2.4. tert-Butyl-(3R,4S)-4-(2-((tert-butyldimethylsilyl)oxy)ethyl)-3-
(hydroxymethyl) piperidine-1-carboxylate (5)
The diol 4 (59.7 g, 148 mmol) was dissolved in dichloromethane
(150 mL) and the solution was stirred at room temperature. A solu-
tion of NaIO4 (34.8 g, 163 mmol) in water (500 mL) was added and
the mixture was stirred vigorously overnight. A solid was filtered
off and discarded. The layers were separated and the water layer
was extracted with dichloromethane (2  100 mL). The organic
layers were combined, dried over Na2SO4 and the solvent was
evaporated to give the corresponding aldehyde (50.92 g, 93%) as
an oil. It was dissolved in MeOH (200 mL) and cooled to 0 C.
NaBH4 (10.35 g, 274 mmol) was added in portions. The resulting
mixture was stirred for 2 h at room temperature. The reaction mix-
ture was concentrated and then dissolved in EtOAc (350 mL) and
water (150 mL) The layers were separated. The water layer was
extracted with EtOAc (2  100 mL). The organic layers were com-
bined, washed with brine, dried with Na2SO4 and the solvent was
evaporated. The product was purified with flash column chro-
matography (heptane/EtOAc, 0% to 20% EtOAc) to give alcohol 5
(37.4 g, 73%) as a colourless oil.4.2.5. tert-Butyl (3R,4S)-3-(ethoxymethyl)-4-(2-hydroxyethyl)
piperidine-1-carboxylate (6a)
Alcohol 5 (5.62 g, 15.05 mmol) was dissolved in THF (dry)
(55 mL) and cooled to 0 C. Sodium hydride (60% dispersion in
mineral oil) (1.204 g, 30.1 mmol, 60%) was added. After removing
the cooling bath, and the mixture was allowed to warmed to room
temperature. After stirring for 30 min at room temperature,
iodoethane (9.39 g, 60.2 mmol, 4.81 mL) was added and the mix-
ture was stirred overnight. The reaction mixture was quenched
with saturated aqueous NH4Cl (165 mL) and the mixture was
extracted with EtOAc (3  165 mL). The organic layers were com-
bined, dried (Na2SO4), filtered and the solvent was evaporated
under reduced pressure to afford the crude (3R,4S)-tert-butyl 4-
(2-((tert-butyldimethylsilyl)oxy)ethyl)-3-(ethoxymethyl)piperidine-
1-carboxylate.
The crude product was dissolved in THF (60 mL) and TBAF (1 M
in THF) (22.58 mmol, 22.58 mL) was added. The reaction mixture
was stirred at room temperature overnight. The reaction mixture
was concentrated under reduced pressure. The product was puri-
fied by column chromatography (0–70% gradient of EtOAc in hep-
tane; TLC H/E 1:1) to afford alcohol 6 (4.15 g, Yield: 96%, 2 steps) as
a light yellow oil.4.2.6. tert-Butyl (3R,4S)-4-(2-hydroxyethyl)-3-(((pyrrolidine-1-
carbonyl)oxy)methyl) piperidine-1-carboxylate (6b)
Alcohol 5 (12.80 g, 34.3 mmol), triphosgene (4.07 g,
13.70 mmol) and potassium carbonate (14.21 g, 103 mmol) were
dissolved in THF (dry) (125 mL) and stirred overnight. The mixture
was cooled to 0 C and pyrrolidine (4.87 g, 68.5 mmol, 5.63 mL)
was added. The mixture was stirred at room temperature over-
night. The reaction was quenched with saturated NH4Cl (350 mL)
and extracted with EtOAc (3  350 mL). The organic layers were
combined, dried (Na2SO4), filtered and the solvent was evaporated
under reduced pressure. The crude product (16.9 g) was used in the
next step without further purification. The crude product (16.9 g)
was dissolved in THF (dry) (125 mL) and TBAF (1 M in THF)
(68.6 mmol, 68.6 mL) was added. The reaction mixture was stirred
at room temperature for 16 h. The reaction mixture was concen-
trated under reduced pressure. The product was purified by flash
column chromatography to get tert-butyl (3R,4S)-4-(2-hydrox-
yethyl)-3-(((pyrrolidine-1-carbonyl)oxy)methyl) piperidine-1-car-
boxylate (6 b) (8.81 g, Yield: 72.1%) as a light yellow oil.
4.2.7. tert-Butyl (3R,4S)-4-(2-(benzyloxy)ethyl)-3-(ethoxymethyl)
piperidine-1-carboxylate
Alcohol 6 (0.74 g, 2.57 mmol) was dissolved in THF (dry)
(20 mL). The solution was cooled (0 C) and NaH (60% dispersion
in mineral oil) (0.257 g, 6.44 mmol, 60%) was added. The resulting
mixture was stirred at room temperature for 30 min. Benzyl bro-
mide (0.440 g, 2.57 mmol, 0.306 mL) was added and the mixture
was stirred at room temperature overnight. The reaction was
quenched with saturated aqueous NH4Cl (25 mL) and extracted
with EtOAc (3  40 mL). The combined organic layers were dried
(Na2SO4), filtered and evaporated under reduced pressure to afford
1.370 g of crude product. Purification by column chromatography
(Reveleris, 120 g column, acidic) followed by evaporation of the
solvents under reduced pressure afforded (3R,4S)-tert-butyl 4-(2-
(benzyloxy)ethyl)-3-(ethoxymethyl)piperidine-1-carboxylate (7a)
(548 mg, Yield: 56.4%) as a colourless oil. 1H NMR (400 MHz,
CDCl3) d 7.39–7.21 (m, 5H), 4.62–4.44 (m, 2H), 4.08 (bs, 2H), 3.64
(s, 1H), 3.59–3.49 (m, 2H), 3.49–3.34 (m, 3H), 3.29 (t, J = 9.0 Hz,
1H), 3.07–2.63 (m, 2H), 2.02–1.76 (m, 1H), 1.77–1.63 (m, 1H),
1.63–1.51 (m, 1H), 1.46 (s, 9H), 1.42–1.11 (m, 2H), 1.19 (t,
J = 6.9 Hz, 3H). 13C NMR (101 MHz, CDCl3) d 155.2, 138.4, 129.5,
128.3, 128.2, 128.2, 127.6, 127.5, 127.0, 126.8, 79.1, 79.1, 72.9,
68.0, 66.5, 66.4, 43.0, 38.2, 28.4, 15.2. ESI-HRMS [C22H35NO4+H]+:
378.26404 found, 378.26389 calculated.
4.2.8. (3R,4S)-tert-Butyl-4-(2-((tert-Butylcarbamoyl)oxy)ethyl)-3-
(ethoxymethyl)piperidine-1-carboxylate (7b)
Alcohol 6a (0.74 g, 2.57 mmol) was dissolved in THF (dry)
(20 mL). The solution was cooled (0 C) and sodium hydride (60%
dispersion in mineral oil) (0.257 g, 6.44 mmol, 60%) was added.
The resulting mixture was stirred at room temperature for
30 min. tert-Butyl isocyanate (0.255 g, 2.57 mmol, 0.294 mL) was
added and the mixture was stirred at room temperature overnight.
The reaction was quenched with saturated aqueous NH4Cl (25 mL)
and extracted with EtOAc (3  40 mL). The combined organic lay-
ers were dried (Na2SO4), filtered and evaporated under reduced
pressure to afford 1.157 g of crude product. Purification by reverse
phase column chromatography (Reveleris, 120 g column, acidic)
followed by evaporation of the solvents under reduced pressure
and coevaporation using CH2Cl2 afforded (3R,4S)-tert-butyl 4-(2-
((tert-butylcarbamoyl)oxy)ethyl)-3-(ethoxymethyl)piperidine-1-
carboxylate (7b) (0.8 g, Yield: 80%)as a colourless oil. 1H NMR
(400 MHz, CDCl3) d 4.60 (s, 1H), 4.07 (d, J = 6.1 Hz, 4H), 3.44 (q,
J = 6.9 Hz, 3H), 3.39 (dd, J = 9.2, 4.4 Hz, 1H), 3.29 (t, J = 9.0 Hz,
1H), 2.87 (s, 2H), 1.88 (s, 1H), 1.77 (s, 1H), 1.70–161 (m, 2H),
1.59–1.40 (m, 11H), 1.28 (d, J = 24.7 Hz, 10H), 1.25–1.13 (m, 3H).
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45.9, 43.0, 38.2, 34.6, 31.7, 28.9, 28.4, 27.8, 15.2. ESI-HRMS [C20H38-
N2O5+H]+: 387.28559 found, 387.28535 calculated.
4.2.9. (3R,4S)-tert-Butyl 4-(2-((tert-butylcarbamoyl)oxy)ethyl)-3-
(((pyrrolidine-1-carbonyl)oxy)methyl)piperidine-1-carboxylate
Alcohol 6b (1.35 g, 3.79 mmol) was dissolved in THF (dry)
(40 mL) and NaH (60% dispersion in mineral oil) (0.379 g,
9.47 mmol, 60%) was added. The resulting mixture was stirred at
room temperature for 30 min. tert-Butyl isocyanate (0.375 g,
3.79 mmol, 0.433 mL) was added and the mixture was stirred at
room temperature overnight. The reaction was quenched with sat-
urated aqueous NH4Cl (25 mL) and extracted with EtOAc
(3  40 mL). The combined organic layers were filtered using a
phase separator and evaporated to dryness under reduced pressure
to afford 2.18 g of crude product. Purification by reverse phase col-
umn chromatography (Reveleris, 120 g column, acidic) followed by
evaporation of the solvents under reduced pressure and coevapo-
ration using CH2Cl2 afforded (3R,4S)-tert-butyl 4-(2-((tert-butylcar-
bamoyl)oxy)ethyl)-3-(((pyrrolidine-1-carbonyl)oxy)methyl)piper-
idine-1-carboxylate (7c) (1.395 g, Yield: 81%) as a colourless oil. 1H
NMR (400 MHz, CDCl3) d 4.89 (s, 1H), 4.22 (s, 1H), 4.08–3.72 (m,
5H), 3.51–3.24 (m, 4H), 2.91 (dd, J = 13.3, 2.2 Hz, 1H), 2.02 (s,
1H), 1.93–1.75 (m, 5H), 1.71 (dd, J = 14.4, 6.9 Hz, 1H), 1.65–1.54
(m, 1H), 1.54–1.36 (m, 2H), 1.44 (s, 9H), 1.32 (s, 9H). 13C NMR
(101 MHz, CDCl3) d 155.0, 154.9, 79.3, 77.3, 76.68, 76.7, 62.2,
61.9, 50.1, 46.1, 45.7, 43.3, 37.1, 35.0, 31.2, 28.9, 28.3, 28.2, 27.8,
25.6, 24.9. ESI-HRMS [C23H41N3O6+H]+: 456.30626 found,
456.30681 calculated.
4.2.10. General procedure for Boc-removal and amidation,
sulfonylation and sulfonylation (8a–8n)
A Boc-protected compound (7a–7c) was dissolved in DCM
(10 mL per mmol). TFA (14 equiv) was added and the resulting
mixture was stirred at room temperature overnight. The reaction
mixture was quenched with sat. K2CO3 (aq) (40 mL) and extracted
three times with Et2O (50 mL). The organic layers were combined,
dried with Na2SO4 and the solvent was concentrated in vacuo to
obtain free amine product that was used as such in next
transformation.
In a screw cap vial (8 mL) was loaded with a solution of amine
(1 equiv) in DCM (2 mL). Et3 N (1.5 equiv) then the corresponding
acid chloride, sulfonyl chloride, chloroformate or isocyanate
(1.2 equiv) were added. The mixture was stirred overnight at room
temperature. The reaction mixture was quenched with 2 mL of 10%
Na2CO3 (aq) and the phases were separated. The aq. layer was
extracted 2 mL of DCM. The solvent was evaporated and the crude
material was purified by column chromatography.
4.2.10.1. 1-((3R,4S)-4-(2-(Benzyloxy)ethyl)-3-(ethoxymethyl)piperi-
din-1-yl)-2-methylpropan-1-one (8a). Colourless liquid, (10.3 mg,
0.030 mmol, 55%). 1H NMR (400 MHz, CDCl3) d 7.45–7.18 (m,
5H), 4.62–4.43 (m, 3H), 4.12 (d, J = 13.4 Hz, 1H), 3.54–3.41 (m,
3H), 3.39–3.34 (m, 2H), 3.28 (t, J = 7.2 Hz), 3.09–2.85 (m, 2H),
2.64 (td, J = 12.9, 3.3 Hz, 1H), 1.94 (s, 2H), 1.63–1.51 (m, 5H), 1.25
(d, J = 9.1 Hz, 1H), 1.18 (t, J = 7.0 Hz, 3H), 1.12 (d, J = 6.7 Hz, 3H),
1.08 (d, J = 6.7 Hz, 3H). 13C NMR (101 MHz, CDCl3) d 176.5, 138.4,
128.4, 127.6, 73.1, 67.8, 66.6, 65.9, 46.9, 41.9, 38.3, 34.8, 32.7,
29.7, 27.6, 20.7, 19.8, 19.1, 15.2. ESI-HRMS [C21H33NO3+H]+:
348.25352 found, 348.25332 calculated.
4.2.10.2. (3R,4S)-4-(2-(Benzyloxy)ethyl)-3-(ethoxymethyl)-1-(methyl-
sulfonyl)piperidine (8b). Colourless liquid, (14.4 mg, 0.041 mmol,
75%). 1H NMR (400 MHz, CDCl3) d 7.42–7.20 (m, 5H), 4.60–4.39
(m, 2H), 3.87–3.73 (m, 1H), 3.67 (dd, J = 7.4, 4.1 Hz, 1H), 3.62–
3.32 (m, 6H), 2.84–2.63 (m, 2H), 2.76 (s, 3H), 2.01 (dt, J = 8.1,4.0 Hz, 1H), 1.85 (tt, J = 11.3, 4.0 Hz, 1H), 1.75–1.33 (m, 4H), 1.18
(t, J = 7.0 Hz, 3H). 13C NMR (101 MHz, CDCl3) d 138.3, 128.4,
127.7, 127.6, 73.0, 67.8, 66.8, 66.7, 47.8, 45.7, 37.7, 34.7, 33.7,
31.9, 27.8, 20.7, 15.2. ESI-HRMS [C18H29NO4S+H]+: 356.18903
found, 356.18901 calculated.
4.2.10.3. 2-((3R,4S)-3-(Ethoxymethyl)-1-(ethylcarbamoyl)piperidin-
4-yl)ethyl tert-butylcarbamate (8c). Colourless liquid, (12.2 mg,
0.034 mmol, 65%). 1H NMR (400 MHz, CDCl3) d 5.02 (t, J = 4.9 Hz,
1H), 4.60 (s, 1H), 4.40–4.30 (m, 1H), 4.05 (t, J = 6.0 Hz, 2H), 3.90–
3.77 (m, 1H), 3.61–3.39 (m, 2H), 3.39–3.30 (m, 2H), 3.32–3.13
(m, 2H), 2.89 (dd, J = 14.1, 2.3 Hz, 1H), 2.67 (td, J = 12.8, 3.2 Hz,
1H), 2.05–1.90 (m, 1H), 1.83 (ddd, J = 11.5, 7.8, 3.8 Hz, 1H), 1.65–
1.39 (m, 3H), 1.38–1.26 (m, 1H), 1.32 (s, 9H), 1.22 ((t, J = 7.4 Hz,
3H), 1.13 (t, J = 7.2 Hz, 3H). 13C NMR (101 MHz, CDCl3) d 158.0,
66.3, 65.8, 61.9, 50.3, 46.4, 43.5, 37.2, 35.6, 35.1, 32.3, 28.9, 27.8,
20.7, 15.6, 15.3. ESI-HRMS [C18H35N3O4+H]+: 358.27019 found,
358.27003 calculated.
4.2.10.4. 2-((3R,4S)-1-Acetyl-3-(ethoxymethyl)piperidin-4-yl)ethyl
tert-butylcarbamate (8d). Colourless liquid, (8.6 mg, 0.026 mmol,
51%). mixture of rotamers 1H NMR (400 MHz, CDCl3) d 4.77–4.43
(m, 2H), 4.04 (dd, J = 13.5, 2.3 Hz, 3H), 3.57–3.24 (m, 4H), 3.03
(dd, J = 13.4, 2.5 Hz, 1H), 2.60 (td, J = 12.8, 3.3 Hz, 1H), 2.09 (s,
3H), 1.97 (dd, J = 7.1, 3.4 Hz, 1H), 1.85 (dd, J = 7.3, 4.1 Hz, 1H),
1.67–1.45 (m, 5H), 1.32 (s, 9H), 1.30–1.24 (m, 1H), 1.18 (t,
J = 7.0 Hz, 3H). 13C NMR (101 MHz, CDCl3) d 169.5, 169.3, 154.9,
154.6, 62.52 61.4, 61.0, 50.1, 47.9, 46.4, 46.1, 45.9, 45.8, 42.7,
41.6, 37.2, 36.8, 31.9, 31.1, 28.9, 28.4, 27.8, 25.8, 24.9, 24.8, 21.5,
21.2. ESI-HRMS [C17H32N2O4+H]+: 329.24366 found, 329.24348
calculated.
4.2.10.5. 2-((3R,4S)-3-(Ethoxymethyl)-1-(furan-3-carbonyl)piperidin-
4-yl)ethyl tert-butylcarbamate (8e). Colourless liquid, (16.3 mg,
0.043 mmol, 83%). 1H NMR (400 MHz, CDCl3) d 7.81 (s, 1H), 7.40
(t, J = 1.6 Hz, 1H), 6.64 (s, 1H), 4.61 (s, 2H), 4.28 (dd, J = 13.3,
1.9 Hz, 1H), 4.08 (d, J = 6.5 Hz, 2H), 3.52–3.22 (m, 4H), 3.16 (dd,
J = 13.3, 3.0 Hz, 1H), 3.01–2.68 (m, 1H), 1.97 (s, 1H), 1.89 (s, 1H),
1.77–1.49 (m, 3H), 1.48–1.24 (m, 1H), 1.39 (s, 9H), 1.13 (t,
J = 9.0 Hz, 3H).
13C NMR (101 MHz, CDCl3) d 164.5, 154.6, 143.2, 142.6, 121.2,
110.3, 77.3, 77.1, 76.7, 62.3, 61.2, 50.2, 46.2, 35.7, 31.4, 28.9,
25.7, 24.9. ESI-HRMS [C20H32N2O5+H]+: 381.23847 found,
381.23840 calculated.
4.2.10.6. 2-((3R,4S)-1-Benzoyl-3-(ethoxymethyl)piperidin-4-yl)ethyl
tert-butylcarbamate (8f). Colourless liquid, (16.6 mg, 0.043 mmol,
82%). 1H NMR (400 MHz, CDCl3) d 7.38 (s, 5H), 4.60 (s, 2H), 4.07
(d, J = 7.1 Hz, 1H), 3.68–3.22 (m, 3H), 3.13 (s, 1H), 1.94 (bs, 2H),
1.65–1.55 (m, 2H), 1.52–1.38 (m, 2H), 1.31 (s, 9H), 1.30–1.14 (m,
4H), 0.96 (s, 3H).13C NMR (101 MHz, CDCl3) d 170.9, 154.8,136.3,
128.3, 127.1, 62.27, 50.2, 46.1, 35.6, 31.5, 28.9, 25.6, 24.9, 20.7.
ESI-HRMS [C26H39N3O6+H]+: 490.29094 found, 490.29116
calculated.
4.2.10.7. Benzyl (3R,4S)-4-(2-((tert-butylcarbamoyl)oxy)ethyl)-3-
(((pyrrolidine-1-carbonyl)oxy)methyl) piperidine-1-carboxylate
(8g). Colourless liquid, (20.3 mg, 0.062 mmol, 65%). 1H NMR
(400 MHz, CDCl3) d 7.49–7.15 (m, 5H), 5.14 (bs, 3H), 4.36 (d,
J = 6.9 Hz, 1H), 4.16 (dt, J = 11.3, 8.8 Hz, 3H), 4.01 (s, 1H), 3.87 (t,
J = 10.5 Hz, 1H), 3.59–3.21 (m, 3H), 3.18–2.98 (m, 3H), 2.06 (s,
1H), 1.95–1.37 (m, 9H), 1.31 (s, 9H). 13C NMR (101 MHz, CDCl3) d
155.7, 136.8, 128.4, 127.9, 127.7, 67.1, 63.1, 62.4, 61.4, 50.2, 46.1,
45.5, 43.8, 36.9 28.9, 27.8, 25.7, 24.8, 20.8, 20.7. ESI-HRMS [C20H32-
N2O5+H]+: 381.23847 found, 381.23840 calculated.
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piperidin-3-yl)methyl pyrrolidine-1-carboxylate (8h). Colourless liq-
uid, (15.1 mg, 0.033 mmol, 52%). major rotamer 1H NMR (400 MHz,
CDCl3) d 7.37 (s, 5H), 5.15–4.90 (m, 1H), 4.60 (s, 1H), 4.50–4.07 (m,
2H), 4.03 (s, 1H), 3.88 (s, 2H), 3.34 (d, J = 28.4 Hz, 3H), 3.23–2.96
(m, 2H), 2.71 (s, 1H), 2.51 (s, 1H), 2.04–1.41 (m, 9H), 1.31 (s, 9H).
13C NMR (101 MHz, CDCl3) d 170.9, 154.8, 136.3, 128.3, 127.1,
62.3, 50.2, 46.1, 35.6, 31.5, 28.9, 25.6, 24.9, 20.7. ESI-HRMS [C25H37-
N3O5+H]+: 460.28046 found, 460.28060 calculated.
4.2.10.9. ((3R,4S)-4-(2-((tert-Butylcarbamoyl)oxy)ethyl)-1-(furan-2-
carbonyl)piperidin-3-yl)methyl pyrrolidine-1-carboxylate (8i). Colour-
less liquid, (16.5 mg, 0.037 mmol, 58%). 1H NMR (400 MHz, CDCl3)
d 7.45 (s, 1H), 6.95 (d, J = 3.4 Hz, 1H), 6.45 (dd, J = 3.4, 1.7 Hz, 1H),
5.12 (s, 1H), 4.59–4.26 (m, 3H), 4.17 (dt, J = 11.2, 5.6 Hz, 1H), 4.03
(s, 1H), 3.88 (t, J = 10.5 Hz, 1H), 3.49–2.83 (m, 5H), 2.17 (s, 1H),
2.05–1.90 (m, 1H), 1.90–1.69 (m, 5H), 1.68–1.47 (m, 4H), 1.30 (d,
J = 13.3 Hz, 9H). 13C NMR (101 MHz, CDCl3) d 160.0, 154.7, 148.1,
143.3, 115.7, 111.1, 62.4, 61.4, 50.2, 46.1, 45.6, 37.4, 35.8, 31.4,
28.9, 25.7, 24.9. ESI-HRMS [C23H35N3O6+H]+: 450.25969 found,
450.25986 calculated.
4.2.10.10. ((3R,4S)-1-Acetyl-4-(2-((tert-butylcarbamoyl)oxy)ethyl)
piperidin-3-yl)methyl pyrrolidine-1-carboxylate (8j). Colourless liq-
uid, (19.5 mg, 0.049 mmol, 77%). Mixture of rotames 1H NMR
(400 MHz, CDCl3) d 5.32 (bs, 1H major), 5.10 (bs, 1H, minor),
4.74–4.40 (m, 2H), 4.04 (dd, J = 13.5, 2.3 Hz, 3H), 3.55–3.25 (m,
4H), 3.03 (dd, J = 13.4, 2.5 Hz, 1H), 2.60 (td, J = 12.8, 3.3 Hz, 1H),
2.09 (d, J = 4.4 Hz, 3H), 1.97 (dd, J = 7.1, 3.4 Hz, 1H), 1.85 (dd,
J = 7.3, 4.1 Hz, 1H), 1.73–1.42 (m, 5H), 1.39–1.26 (m, 10H), 1.18
(dt, J = 10.8, 7.0 Hz, 3H). 13C NMR (101 MHz, CDCl3) d 169.5,
154.6, 62.5, 62.3, 61.4, 61.0, 47.9, 46.4, 46.1, 45.9, 45.8, 42.7,
41.6, 37.2, 36.84, 31.9, 31.1, 28.9, 27.8, 25.8, 25.7, 24.9, 24.8,
21.5, 21.2, 20.7. ESI-HRMS [C20H35N3O5+H]+: 398.26413 found,
398.26495 calculated.
4.2.10.11. ((3R,4S)-4-(2-((tert-Butylcarbamoyl)oxy)ethyl)-1-(2-methoxy-
acetyl)piperidin-3-yl)methyl pyrrolidine-1-carboxylate (8k). Colour-
less liquid, (19.6 mg, 0.046 mmol, 72%). mixture of rotames 1H
NMR (400 MHz, CDCl3) d 5.25 (s, 1H, major), 5.13 (s, 1H, minor),
4.50 (t, J = 12.1 Hz, 2H), 4.18 (bs, 1 H, minor), 4.25–4.10 (m, 2H),
4.08 (d, J = 7.0 Hz, 1H), 4.02 (d, J = 12.0 Hz, 1H), 3.90 (d,
J = 13.7 Hz, 1H), 3.85–3.69 (m, 1H), 3.54–3.24 (m, 3H), 3.41 (s,
3H), 3.09 (d, J = 11.5 Hz, 1H), 2.93–2.82 (m, 1H), 2.74 (s, 1H), 2.15
(s, 1H), 1.99–1.78 (m, 4H), 1.78–1.64 (m, 2H), 1.65–1.50 (m, 2H),
1.42–1.38 (m, 1H), 1.32 (s, 10H). 13C NMR (101 MHz, CDCl3) d
168.1, 154.6, 98.4, 71.9, 71.1, 62.5, 61.2, 59.0, 50.1, 46.4, 46.1,
5.8, 44.6, 43.10, 41.9, 37.2, 36.8, 35.5, 31.7, 31.2, 28.9, 28.4, 27.7,
25.8, 24.9, 20.7, 20.6. ESI-HRMS [C21H37N3O6+H]+: 428.27542
found, 381.27551 calculated.
4.2.10.12. ((3R,4S)-4-(2-((tert-Butylcarbamoyl)oxy)ethyl)-1-pival-
oylpiperidin-3-yl)methyl pyrrolidine-1-carboxylate (8l). Colourless
liquid, (20.7 mg, 0.047 mmol, 74%). mixture of rotames 1H NMR
(400 MHz, CDCl3) d 4.91 (s, 1H), 4.27 (dd, J = 10.7, 4.3 Hz, 1H),
4.15 (dt, J = 11.4, 5.4 Hz, 2H), 4.08–3.91 (m, 2H), 3.86 (t,
J = 10.2 Hz, 1H), 3.37 (td, J = 6.4, 2.9 Hz, 4H), 3.26 (ddd, J = 13.2,
9.7, 3.4 Hz, 1H), 3.13 (d, J = 11.3 Hz, 1H), 2.09 (dt, J = 8.6, 4.5 Hz,
1H), 1.97–1.78 (m, 5H), 1.78–1.53 (m, 3H), 1.47 (ddd, J = 13.0,
9.2, 4.4 Hz, 1H), 1.31 (d, J = 3.7 Hz, 9H), 1.28 (s, 9H). 13C NMR
(101 MHz, CDCl3) d 176.9, 154.9, 62.3, 62.2, 50.2, 46.2, 45.8, 45.5,
44.7, 38.8, 38.0, 34.8, 30.2, 28.9, 28.4, 25.8, 24.9, 20.7. ESI-HRMS
[C23H41N3O5+H]+: 440.31168 found, 440.31190 calculated.
4.2.10.13. ((3R,4S)-4-(2-((tert-Butylcarbamoyl)oxy)ethyl)-1-propi-
onylpiperidin-3-yl)methyl pyrrolidine-1-carboxylate (8m). Colour-less liquid, (20.4 mg, 0.049 mmol, 78%). mixture of rotamers 1H
NMR (400 MHz, CDCl3) d 5.27 (s, 1H, major), 5.07 (s, 1H, minor),
4.54 (t, J = 13.8 Hz, 2H), 4.38–4.25 (m, 1H, minor), 4.24–4.07 (m,
1H), 4.07–3.87 (m, 2H), 3.79 (dd, J = 23.4, 10.9 Hz, 1H), 3.79 (dd,
J = 23.4, 10.9 Hz, 1H), 3.46–3.30 (m, 4H), 3.07 (dd, J = 18.4, 6.9 Hz,
1H), 2.98–2.81 (m, 1H, minor), 2.68 (s, 1H), 2.38 (dd, J = 13.3,
7.7 Hz, 2H), 2.12 (d, J = 5.0 Hz, 1H), 1.98–1.77 (m, 5H), 1.77–1.64
(m, 2H), 1.64–1.48 (m, 2H), 1.40–1.32 (m, 1H), 1.32 (s, 9H), 1.13
(t, J = 7.4 Hz, 3H). 13C NMR (101 MHz, CDCl3) d 172.8, 154.2, 63.0,
62.5, 62.3, 61.6, 61.2, 50.11, 46.9, 46.3, 46.1, 45.7, 44.9, 42.8,
41.7, 37.3, 37.0, 36.4, 31.7, 31.0, 28.9, 28.5, 27.9, 26.7, 25.9, 25.8,
24.9, 20.7, 9.6, 9.5. ESI-HRMS [C21H37N3O5+H]+: 412.28036 found,
412.28060 calculated.4.2.10.14. ((3R,4S)-4-(2-((tert-Butylcarbamoyl)oxy)ethyl)-1-(2-
ethoxyacetyl)piperidin-3-yl)methyl pyrrolidine-1-carboxylate
(8n). Colourless liquid, (19.0 mg, 0.043 mmol, 68%). mixture of
rotames 1H NMR (400 MHz, CDCl3) d 5.24–5.19 (m, 1H), 4.48 (d,
J = 9.5 Hz, 1H), 4.41–4.30 (m, 1H), 4.30–4.08 (m, 3H), 4.09–3.91
(m, 2H), 3.87–3.74 (m, 1H), 3.55 (qd, J = 7.0, 4.0 Hz, 2H), 3.39–
3.30 (m, 4H), 3.11 (d, J = 12.8 Hz, 1H), 2.76 (s, 1H), 2.14 (s, 1H),
1.94–1.87 (m, 5H), 1.78–1.66 (m, 2H), 1.69–1.67 (m, 1H), 1.57 (s,
2H), 1.50–1.36 (m, 1H), 1.32 (s, 9H), 1.23 (t, J = 7.0 Hz, 3H). 13C
NMR (101 MHz, CDCl3) d 168.4, 154.6 70.4, 69.5, 66.8, 62.5, 62.3,
61.3, 50.1, 46.4, 46.1, 45.8, 44.8, 43.1, 41.8, 37.2, 36.9, 31.6, 31.2,
28.9, 28.4, 27.7, 25.8, 24.9, 20.7, 15.1. ESI-HRMS [C22H39N3O6+H]+:
442.29108 found, 442.29116 calculated.4.2.11. Synthesis of tert-butyl (3R,4S)-4-(2-((tert-butyldimethylsilyl)
oxy)ethyl)-3-(-oxiran-2-yl) piperidine-1-carboxylates (9)
Diol 4 (1.1 g, 2.6 mmol) was dissolved in dry dichloromethane
(14 mL). Trimethyl orthoacetate (1 mL, 7.8 mmol) and PPTs
(65 mg, 0.2 mmol) were added and the mixture was stirred over-
night. The product concentrated and dissolved in 16 mL anhydrous
CH2Cl2. TMSCl (985 lL, 7.8 mmol) was added and stirring was con-
tinued for 4 h. The solvent was evaporated and the crude mixture
was dissolved in 16 mL methanol. K2CO3 (1.1 g, 7.8 mmol) was
added and the resultant mixture was stirred for 2 h. The reaction
was quenched with saturated NH4Cl and the mixture was
extracted with dichloromethane (3x15 mL). The organic layers
were combined, washed with brine and dried with MgSO4 to get
mixture of epoxides 9 (0.85 gm, 80%). The crude mixture was then
purified by column chromatography to get epoxides 9a and 9b.4.2.11.1. (3R,4S)-tert-butyl-4-(2-((tert-Butyldimethylsilyl)oxy)ethyl)-
3-((R)-oxiran-2-yl)piperidine-1-carboxylate (9a). 1H NMR
(400 MHz, CDCl3) d 4.09 (bs, 1H), 4.00 (d, J = 12.8 Hz, 1H), 3.71
(dd, J = 12.5, 6.2 Hz, 2H), 3.04–2.90 (m, 2H), 2.83 (s, 1H), 2.74 (t,
J = 4.4 Hz, 1H), 2.50 (dd, J = 5.0, 2.7 Hz, 1H), 1.97 (dd, J = 6.9,
4.1 Hz, 1H), 1.78 (dd, J = 13.6, 6.7 Hz, 1H), 1.67–1.52 (m, 3H), 1.45
(s, 9H), 1.35 (dd, J = 7.7, 3.7 Hz, 1H), 0.89 (s, 9H), 0.05 (s, 6H). 13C
NMR (101 MHz, CDCl3) d 154.5, 79.3, 60.4, 50.6, 45.1, 41.0, 35.4,
34.5, 28.3, 27.7, 25.8, 18.2, 5.7. ESI-HRMS [C20H39NO4Si+H]+:
386.27227 found, 386.27211 calculated.4.2.11.2. (3R,4S)-tert-butyl-4-(2-((tert-Butyldimethylsilyl)oxy)ethyl)-
3-((S)-oxiran-2-yl)piperidine-1-carboxylate (9b). 1H NMR (400 MHz,
CDCl3) d 4.19 (d, J = 12.5 Hz, 3H), 3.84–3.51 (m, 4H), 3.04–2.68 (m,
7H), 2.59 (d, J = 2.5 Hz, 2H), 1.88 (ddd, J = 16.9, 9.1, 4.7 Hz, 2H),
1.80–1.36 (m, 26H), 1.35–1.12 (m, 3H), 0.89 (d, J = 9.3 Hz, 17H),
0.04 (s, 11H). 13C NMR (101 MHz, CDCl3) d 155.12, 79.52, 77.20,
60.73, 50.01, 48.40, 46.95, 43.25, 42.01, 35.90, 34.63, 28.33,
28.33, 27.71, 25.92, 25.92, 18.31, 5.35. ESI-HRMS [C20H39NO4Si
+H]+: 386.27212 found, 386.27211 calculated.
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oxiran-2-yl)piperidine-1-carboxylate (10a)
The epoxide 9a (0.4 g, 1.03 mmol) was dissolved in THF (15 mL)
and TBAF (1.5 mL, 1 M in THF, 1.5 mmol) was drop wise added. The
mixture was stirred for 2 h and then the crude material was con-
centrated. The product was purified by column chromatography
(PE/EtOAc 1:1) to get epoxy alcohol tert-butyl (3R,4S)-4-(2-hydrox-
yethyl)-3-((R)-oxiran-2-yl)piperidine-1-carboxylate (10a) (270mg).
1H NMR (400 MHz, CDCl3) d 4.38–3.92 (m, 2H), 3.83–3.60 (m,
2H), 3.13–2.98 (m, 2H), 2.94 (d, J = 12.0 Hz, 1H), 2.88–2.73 (m,
3H), 2.53 (dd, J = 4.8, 2.7 Hz, 1H), 1.95 (dt, J = 11.8, 7.5 Hz, 1H),
1.83 (td, J = 13.8, 7.1 Hz, 1H), 1.72–1.51 (m, 3H), 1.47 (s, 9H). 13C
NMR (101 MHz, CDCl3) d 154.5, 79.4, 60.3, 50.7, 47.2, 45.3, 44.2,
43.4, 40.9, 40.7, 35.5, 35.4, 28.2, 27.9. ESI-HRMS [C14H25NO4+H]+:
272.18565 found, 272.18563 calculated.
4.2.13. Synthesis of tert-butyl (1R,4aS,8aR)-1-(hydroxymethyl)
hexahydro-1H-pyrano[3,4-c]pyridine-7(3H)-carboxylate (11)
tert-Butyl (3R,4S)-4-(2-hydroxyethyl)-3-((R)-oxiran-2-yl)piper-
idine-1-carboxylate (10a). (260 mg, 0.96 mmol) and PPTs (65 mg,
0.26 mmol) were dissolved in 15 mL of dry acetonitrile and the
resulting mixture was stirred overnight at 75 C. The crude mate-
rial was concentrated and directly purified with flash column chro-
matography (PE/EtOAc 1:1) to get cyclic ether 11 (190 mg, 73%)
and 110 (26 mg, 10%) as colourless oil.
4.2.13.1 (11). 1H NMR (400 MHz, DMSO) d 4.33 (s, 1H), 3.95 (d,
J = 10.8 Hz, 1H), 3.78 (t, J = 12.8 Hz, 2H), 3.52–3.24 (m, 4H), 2.84
(t, J = 11.7 Hz, 2H), 1.96 (d, J = 15.3 Hz, 2H), 1.79–1.57 (m, 2H),
1.41 (s, 10H), 1.19 (d, J = 7.4 Hz, 1H). 13C NMR (101 MHz, DMSO)
d 153.9, 79.8, 78.0, 67.1, 61.3, 38.5, 38.3, 35.2, 31.5, 30.0, 27.8, 24.2.
4.2.13.2. tert-Butyl (4aS,9R,9aR)-9-hydroxyoctahydrooxepino[4,5-c]
pyridine-2(1H)-carboxylate (110). 1H NMR (400 MHz, DMSO) d
4.34 (s, 1H), 3.82 (dd, J = 12.8, 4.9 Hz, 1H), 3.74–3.52 (m, 4H),
3.52–3.31 (m, 3H), 3.12 (d, J = 13.2 Hz, 1H), 3.01 (t, J = 9.1 Hz,
1H), 2.06 (d, J = 20.6 Hz, 1H), 1.76 (dd, J = 16.8, 10.5 Hz, 2H), 1.59
(d, J = 19.0 Hz, 2H), 1.47–1.38 (m, 2H), 1.43 (s, 9H), 1.08 (t,
J = 6.9 Hz, 1H). 13C NMR (101 MHz, DMSO) d 154.1, 78.0, 70.6,
69.3, 66.1, 55.8, 45.1, 44.9, 42.4, 34.0, 31.3, 27.9, 27.8, 18.1.
4.2.14. Synthesis of tert-butyl (1R,4aS,8aR)-1-((methoxy)methyl)
hexahydro-1H-pyrano[3,4-c]pyridine-7(3H)-carboxylate (13a)
To a suspension of sodium hydride (60% suspension in mineral
oil) (0.035 g, 0.85 mmol) in dry DMF (5.0 mL) under argon atmo-
sphere at 0 C was added alcohol 11 (190 mg, 0.7 mmol) as DMF
solution. The reaction mixture was stirred at 0 C for 15 min and
methyl iodide (82 mL, 1.32 mmol) was added and stirred at ambient
temperatures for 5 h. After completion, the reaction mixture was
cooled at 0 C and quenched with water and extracted with diethyl
ether (2  15 mL). All organic layers were combined, washed with
brine, dried over MgSO4 and concentrated in vacuo. The residue
obtained was subjected to column chromatography to get pure
tert-butyl (1R,4aS,8aR)-1-(methoxymethyl)hexahydro-1H-pyrano
[3,4-c]pyridine-7(3H)-carboxylate (13a-Boc). 1H NMR (400 MHz,
CDCl3) d 4.09 (dd, J = 10.8, 3.9 Hz, 1H), 3.97–3.73 (m, 2H), 3.99–
3.71 (m, 2H), 3.67–3.22 (m, 4H), 3.37 (s, 3H), 3.02–2.66 (m, 2H),
2.11–1.89 (m, 2H), 1.81–1.63 (m, 2H), 1.52–1.36 (s, 1H) 1.47 (s,
9H). 13C NMR (101 MHz, CDCl3) d 154.9, 79.3, 78.6, 73.9, 78.7,
74.3, 72.7, 68.3, 67.8, 67.5, 63.0, 59.1, 40.8, 40.57, 39.2, 36.4,
32.2, 32.0, 30.6, 29.6, 28.4, 28.3, 24.6. ESI-HRMS [C15H27NO4+H]+:
286.20127 found, 286.20128 calculated.
To this compound methanolic HCl (4.0 M, 2.0 mL) was added
and the reaction mixture was stirred at room temperature for
5 h. The reaction was monitored by TLC and after consumption of
all starting material; the reaction mixture was concentrated todryness. The residue obtained was co-evaporated with toluene to
remove traces of water. The crude compound was washed
with diethyl ether (3  15 mL) to get amine as hydrochloride
salt (1R,4aS,8aR)-1-((methoxy)methyl)octahydro-1H-pyrano[3,4-c]
pyridin-7-ium chloride (13a) (108 mg, 70% yields over 2 steps).
1H NMR (400 MHz, CDCl3) d 9.15 (s, 1H), 8.76 (s, 1H), d 4.13 (dd,
J = 11.3, 4.4 Hz, 1H), 3.61 (d, J = 13.8 Hz, 1H), 3.79 (bs, 2H), 3.52
(t, J = 11.8 Hz, 1H), 3.46–3.23 (m, 3H), 3.39 (s, 3H), 3.17 (dd,
J = 23.9, 11.9 Hz, 1H), 3.02 (dd, J = 23.9, 12.5 Hz, 1H), 2.29–2.23
(m, 2H), 2.13 (d, J = 14.8 Hz, 1H), 2.04–1.87 (m, 1H), 1.71 (d,
J = 14.3 Hz, 1H), 1.35 (d, J = 13.7 Hz, 1H). 13C NMR (101 MHz,
CDCl3) d 77.5, 72.8, 68.1, 59.3, 39.5, 39.2, 33.8, 30.6, 27.3, 24.3.
ESI-HRMS [C10H19NO2+H]+: 186.14873 found, 186.14885
calculated.
4.2.15. Synthesis of (1R,4aS,8aR)-1-((benzyloxy)methyl)octahydro-
1H-pyrano[3,4-c]pyridin-7-ium chloride (13b)
To a suspension of sodium hydride (60% suspension in mineral
oil) (0.050 g, 1.2 mmol) in dry DMF (5.0 mL) under argon atmo-
sphere at 0 C was added alcohol 11 (272 mg,1.0 mmol) as DMF
solution. The reaction mixture was stirred at 0 C for 15 min and
an alkyl halide (1.32 mmol) was added and stirred at ambient tem-
peratures for 5 h. After completion, the reaction mixture was
cooled at 0 C and quenched with water and extracted with diethyl
ether (2  15 mL). All organic layers were combined, washed with
brine, dried over MgSO4 and concentrated in vacuo. The residue
obtained was subjected to column chromatography to get pure
product tert-butyl (1S,4aS,8aR)-1-(methoxymethyl)hexahydro-
1H-pyrano[3,4-c]pyridine-7(3H)-carboxylate (13b-Boc).
To this compound methanolic HCl (4.0 M, 3.0 mL) was added
and the reaction mixture was stirred at room temperature for over-
night. The reaction was monitored by TLC and after consumption of
all starting material; the reaction mixture was concentrated to dry-
ness. The residue obtained was co-evaporated with toluene to
remove traces of water. The crude compound was washed with
diethyl ether (3  15 mL) to get amine as hydrochloride salt 13b
(238 mg, 80% yields over 2 steps). 1H NMR (400 MHz, CDCl3) d
7.43–7.16 (m, 5H), 4.61 (d, J = 12.1 Hz, 1H), 4.51 (d, J = 12.1 Hz,
1H), 4.18–4.04 (m, 1H), 3.85 (s, 2H), 3.71–3.59 (m, 1H), 3.57–
3.32 (m, 3H), 2.92–2.84 (m, 2H), 2.01 (t, J = 9.3 Hz, 2H), 1.75 (d,
J = 9.7 Hz, 2H), 1.46–1.42 (m, 1H), 1.43 (s, 9H), 1.22 (d,
J = 10.4 Hz, 1H). 13C NMR (101 MHz, CDCl3) d 155.0, 137.9, 128.3,
127.8, 127.6, 79.3, 78.7, 73.5, 71.02, 68.3, 39.0, 36.3, 32.2, 30.6,
28.4, 24.6. ESI-HRMS [C16H23NO2+H]+: 262.18013 found,
262.18016 calculated.
4.2.16. tert-Butyl (3S,4S)-4-(2-hydroxyethyl)-3-((R)-oxiran-2-yl)
piperidine-1-carboxylate (10b)
The epoxide 9b (0.4 gm, 1.03 mmol) was dissolved in 15 mL of
THF and TBAF (1.5 mL, 1 M in THF, 1.5 mmol) was drop wise added.
The mixture was stirred for 2 h and then the crude material was
concentrated. The products ware purified by column chromatogra-
phy (PE/EtOAc 1:1) to get tert-butyl (3S,4S)-4-(2-hydroxyethyl)-3-
((R)-oxiran-2-yl)piperidine-1-carboxylate (10b) (270 mg).
1H NMR (400 MHz, CDCl3) d 4.33–3.95 (m, 2H), 3.71 (td, J = 10.7,
3.9 Hz, 2H), 3.04–2.68 (m, 4H), 2.61 (s, 1H), 2.15–1.83 (m, 2H),
1.83–1.51 (m, 4H), 1.50–1.40 (m, 1H), 1.47 (s, 9H), 1.35–1.25 (m,
1H). 13C NMR (101 MHz, CDCl3) d 155.1, 79.6, 77.3, 77.0, 76.7,
60.0, 49.8, 48.3, 46.9, 43.2, 41.8, 35.7, 34.4, 29.6, 28.3, 28.2, 27.6.
ESI-HRMS [C14H25NO4+H]+: 272.18564 found, 272.18563
calculated.
4.2.17. tert-Butyl (1S,4aS,8aR)-1-(hydroxymethyl)hexahydro-1H-
pyrano[3,4-c]pyridine-7(3H)-carboxylate (12)
This epoxide (260 mg, 0.96 mmol) and PTSA (65 mg,
0.26 mmol) were dissolved in 15 mL of dry acetonitrile and the
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rial was concentrated and directly purified with flash column chro-
matography (PE/EtOAc 1:1) to get cyclic ether 12 (182 mg, 70%)
and tert-butyl (4aS,9S,9aR)-9-hydroxyoctahydrooxepino[4,5-c]pyr-
idine-2(1H)-carboxylate (120) (40 mg, 15%) as colourless oil.
1H NMR (400 MHz, DMSO) d 4.11 (s, 1H), 3.93 (d, J = 13.5 Hz,
2H), 3.72–3.46 (m, 4H), 3.44–3.26 (m, 1H), 3.10 (s, 1H), 2.80 (d,
J = 13.2 Hz, 2H), 1.97 (s, 1H), 1.92–1.69 (m, 3H), 1.42–1.36 (m,
1H) 1.39 (s, 9H). 13C NMR (101 MHz, DMSO) d 153.5, 78.2, 74.0,
62.1, 61.5, 44.6, 42.9, 39.9, 39.7, 39.5, 39.3, 39.1, 34.8, 30.7,
30.08, 27.8, 25.2, 20.0.
4.2.18. tert-Butyl (4aS,9S,9aR)-9-hydroxyoctahydrooxepino[4,5-c]
pyridine-2(1H)-carboxylate (120)
1H NMR (400 MHz, CDCl3) d 4.06 (dd, J = 9.0, 5.1 Hz, 1H), 3.97–
3.87 (m, 1H), 3.87–3.77 (m, 1H), 3.75–3.64 (m, 2H), 3.60–3.49 (m,
2H), 3.38 (dd, J = 13.4, 9.5 Hz, 1H), 3.28 (s, 1H), 2.71 (s, 1H), 2.19–
1.84 (m, 3H), 1.79–1.54 (m, 3H), 1.49 (d, J = 23.8 Hz, 9H). 13C
NMR (101 MHz, CDCl3) d 155.3, 79.4, 72.6, 70.6, 68.5, 43.6, 42.3,
34.7, 32.5, 31.4, 28.4, 28.4, 20.7.
4.2.19. Synthesis of (1S,4aS,8aR)-1-((benzyloxy)methyl)octahydro-
1H-pyrano[3,4-c]pyridin-7-ium chloride (14)
To a suspension of sodium hydride (60% suspension in mineral
oil) (50 mg, 1.2 mmol) in dry DMF (5.0 mL) under argon atmo-
sphere at 0 C was added alcohol 6a (0.7 mmol) as DMF solution.
The reaction mixture was stirred at 0 C for 15 min and an alkyl
halide (1.32 mmol) was added and stirred at ambient temperatures
for 5 h. After completion, the reaction mixture was cooled at 0 C
and quenched with water and extracted with diethyl ether
(2  15 mL). All organic layers were combined, washed with brine,
dried over MgSO4 and concentrated in vacuo. The residue obtained
was subjected to column chromatography to get pure tert-butyl
(1S,4aS,8aR)-1-((benzyloxy)methyl)hexahydro-1H-pyrano[3,4-c]
pyridine-7(3H)-carboxylate 14-Boc: 1H NMR (400 MHz, CDCl3) d
7.47–7.19 (m, 5H), 4.79–4.41 (m, 2H), 4.30–3.88 (m, 3H), 3.88–
3.54 (m, 5H), 2.75 (bd, J = 14.0 Hz, 2H), 2.01–1.98 (m, 4H), 1.60–
1.21 (m, 3H), 1.37 (s, 9H). 13C NMR (101 MHz, CDCl3) d 154.3,
138.3, 128.2, 127.5, 79.4, 73.5, 72.98, 70.9, 63.0, 45.8, 43.4, 35.3,
31.8, 30.9, 28.3, 25.3. ESI-HRMS [C21H31NO4+H]+: 362.23263 found,
362.23258 calculated. To above compound, methanolic HCl (4.0 M,
2.0 mL) was added and the reaction mixture was stirred at room
temperature for overnight. The reaction was monitored by TLC
and after consumption of all starting material; the reaction mix-
ture was concentrated to dryness. The residue obtained was co-
evaporated with toluene to remove traces of water. The crude com-
pound was washed with diethyl ether (3  15 mL) to get free
amine as hydrochloride salt 14 (232 mg, 78% yields over 2 steps).
1H NMR (400 MHz, CDCl3) d 9.38 (s, 1H), 9.12 (s, 1H), 7.39–7.20
(m, 5H), 5.69 (s, 1H), 4.59 (d, J = 12.1 Hz, 1H), 4.51 (d, J = 12.0 Hz,
1H), 4.03 (s, 1H), 3.87–3.52 (m, 4H), 3.31 (s, 2H), 2.93 (s, 2H),
2.28 (s, 1H), 2.06 (s, 2H), 1.90–1.61 (m, 2H), 1.52 (d, J = 11.7 Hz,
1H). 13C NMR (101 MHz, CDCl3) d 137.9, 128.3, 127.6, 127.5, 73.3,
72.4, 69.7, 62.4, 43.8, 42.6, 32.7, 28.9, 23.1. ESI-HRMS [C16H23NO2+-
H]+: 262.18011 found, 262.18016 calculated.
4.2.20. General procedure for Synthesis of library molecules 15, 16
To the solution of amine hydrochloride 13a-b/14 (20 mg;
1 equiv) in dichloromethane (2.0 mL), triethylamine (3.0 eq) and
DMAP (catalytic amount) followed by respective reagent
(1.2 equiv) was added. The reaction mixture was stirred at room
temperature for 3 h (alternatively can be left overnight). After
completion, the reaction mixture was diluted with water and
extracted with dichloromethane; the organic layers were com-
bined, washed with brine, dried over MgSO4, and concentrated invacuo. The crude product was purified by column chromatography
get to pure title compounds (75–90%).
4.2.20.1. ((1R,4aS,8aR)-1-(methoxymethyl)hexahydro-1H-pyrano[3,4-
c]pyridin-7(3i)-yl)(phenyl) methanone (15a). Colourless liquid
(21 mg, 82%), 1H NMR (400 MHz, CDCl3) d 7.39 (s, 5H), 4.54 (bd,
J = 11.7 Hz, 1H), 4.11 (bd, J = 10.1 Hz, 1H), 3.70–3.42 (m, 3H), 3.43
(s, 3H), 3.31–2.73 (m, 4H), 2.09 (s, 4H), 1.99–1.53 (m, 3H), 1.48–
1.19 (m, 1H). 13C NMR (101 MHz, CDCl3) d 170.5, 136.2, 129.4,
128.4, 128.3, 126.7, 78.8, 77.4, 74.0, 72.25, 68.3, 59.3, 59.0, 43.1,
37.5, 37.3, 37.2, 36.6, 32.3, 31.5, 30.5, 24.8, 24.7. ESI-HRMS [C17H23-
NO3+H]+: 290.17499 found, 290.17507 calculated.
4.2.20.2. (1R,4aS,8aR)-7-(Mesitylsulfonyl)-1-(methoxymethyl)octahy-
dro-1H-pyrano[3,4-c]pyridine (15b). Colourless liquid (26.5 mg,
80%), 1H NMR (400 MHz, CDCl3) d 6.95 (s, 2H), 4.08 (d, J = 9.5 Hz,
1H), 3.56 (d, J = 4.1 Hz, 1H), 3.52–3.23 (m, 5H), 3.32 (s, 3H), 3.04
(t, J = 12.4 Hz, 1H), 2.90 (t, J = 12.9 Hz, 1H), 2.61 (s, 6H), 2.30 (s,
3H), 2.01 (d, J = 11.8 Hz, 2H), 1.86 (dd, J = 17.8, 13.5 Hz, 2H), 1.51
(d, J = 13.6 Hz, 1H), 1.27–1.16 (m, 1H). 13C NMR (101 MHz, CDCl3)
d 142.3, 140.2, 131.8, 131.7, 81.1, 78.1, 73.3, 68.3, 67.53, 67.3,
59.1, 57.1, 40.2, 40.0, 39.9, 39.5, 39.1, 36.1, 32.7, 32.2, 31.9,
30.13, 24.4, 22.8, 22.7, 20.9. ESI-HRMS [C19H29NO4S+H]+:
368.18891 found, 368.18901 calculated.
4.2.20.3. Isopropyl (1R,4aS,8aR)-1-(methoxymethyl)hexahydro-1H-
pyrano[3,4-c]pyridine-7(3H)-carboxylate (15c). Colourless liquid
(18.6 mg, 76%), 1H NMR (400 MHz, CDCl3) d 4.92 (sept, J = 6.4 Hz,
1H), 4.12 (dd, J = 10.8, 4.0 Hz, 1H), 4.04–3.73 (m, 2H), 3.65–3.29
(m, 4H), 3.41 (s, 3H), 3.00 (t, J = 12.8 Hz, 1H), 2.88 (t, J = 12.8 Hz,
1H), 2.21–1.92 (m, 2H), 1.87–1.65 (m, 3H), 1.47 (d, J = 13.3 Hz,
1H), 1.25 (d, J = 6.3 Hz, 6H). 13C NMR (101 MHz, CDCl3) d 155.4,
78.6, 77.4, 77.1, 76.7, 68.5, 68.4, 67.9, 67.6, 59.3, 39.0, 38.9, 36.5,
32.3, 32.1, 30.6, 24.7, 22.3, 22.2. ESI-HRMS [C14H25NO4+H]+:
272.18571 found, 272.18563 calculated.
4.2.20.4. Isopropyl (1R,4aS,8aR)-1-((benzyloxy)methyl)hexahydro-
1H-pyrano[3,4-c]pyridine-7(3H)-carboxylate (15d). Colourless liq-
uid (18.2 mg, 75%), 1H NMR (400 MHz, CDCl3) d 7.51–7.22 (m,
5H), 4.90 (dt, J = 12.5, 6.3 Hz, 1H), 4.63 (d, J = 12.1 Hz, 1H), 4.53
(d, J = 12.1 Hz, 1H), 4.11 (dd, J = 10.8, 3.8 Hz, 1H), 3.90 (d,
J = 11.1 Hz, 2H), 3.73–3.35 (m, 4H), 2.99 (t, J = 12.4 Hz, 1H), 2.87
(t, J = 12.9 Hz, 1H), 2.14–1.93 (m, 2H), 1.84–1.67 (m, 1H), 1.52–
1.41 (m, 1H), 1.34–1.14 (m, 8H). 13C NMR (101 MHz, CDCl3) d
155.4, 137.8, 128.4, 127.6, 78.8,, 73.6, 70.9, 68.4, 39.0, 36.5, 32.4,
30.6, 24.49, 22.2, 21.8, 21.6. ESI-HRMS [C20H29NO4+H]+:
348.21697 found, 348.21693 calculated.
4.2.20.5. ((1R,4aS,8aR)-1-((benzyloxy)methyl)hexahydro-1H-pyrano
[3,4-c]pyridin-7(3H)-yl)(phenyl) methanone (15e). Colourless liquid,
(19.6 mg, 80%), 1H NMR (400 MHz, CDCl3) d 7.50–7.19 (m, 9H), 7.15
(s, 1H), 4.68 –4.48 (m, 2H), 4.27 (dd, J = 24.6, 11.4 Hz, 1H), 4.11 (dd,
J = 24.1, 9.9 Hz, 1H), 3.67–3.57 (m, 4H), 3.27–2.80 (m, 3H), 2.06 (bs,
2H), 1.90 (d, J = 11.7 Hz, 1H), 1.78–1.53 (m, 1H), 1.33–1.16 (m, 1H).
13C NMR (101 MHz, CDCl3) d 170.5, 137.9, 136.3, 129.4, 128.4,
127.9, 127.7, 126.7, 78.9, 77.6, 73.6, 73.3, 71.2, 69.7, 68.31, 43.0,
37.3, 36.5, 32.3, 31.5, 30.5, 24.8. ESI-HRMS [C23H27NO3+H]+:
366.20660 found, 366.20637 calculated.
4.2.20.6. Ethyl (1R,4aS,8aR)-1-((benzyloxy)methyl)hexahydro-1H-
pyrano[3,4-c]pyridine-7(3H)-carboxylate (15f). Colourless liquid
(19 mg, 85%), 1H NMR (400 MHz, CDCl3) d 7.46–7.21 (m, 5H),
4.63 (d, J = 12.1 Hz, 1H), 4.52 (d, J = 12.1 Hz, 1H), 4.12 (dd,
J = 12.6, 6.2 Hz, 3H), 3.91 (bs, 2H), 3.67–3.36 (m, 4H), 3.00 (t,
J = 12.3 Hz, 1H), 2.90 (t, J = 12.3 Hz, 1H), 2.15–1.92 (m, 2H), 1.78
(d, J = 10.4 Hz, 2H), 1.56–1.41 (m, 1H), 1.34–1.14 (m, 1H), 1.24 (t,
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128.4, 127.8, 127.7, 78.8, 73.6, 71.0, 68.4, 61.2, 39.0, 38.9, 36.3,
32.2, 30.6, 24.7, 14.7. ESI-HRMS [C19H27NO4+H]+: 334.20103 found,
334.20128 calculated.
4.2.20.7. (1R,4aS,8aR)-1-((Benzyloxy)methyl)-N-(tert-butyl)hexahy-
dro-1H-pyrano[3,4-c]pyridine-7(3H)-carboxamide (15g). Colourless
liquid (21.8 mg, 90%), 1H NMR (400 MHz, CDCl3) d 7.37–7.24 (m,
5H), 4.61 (d, J = 12.2 Hz, 1H), 4.52 (d, J = 12.2 Hz, 1H), 4.30 (s,
1H), 4.09 (dd, J = 11.6, 3.5 Hz, 1H), 3.76–3.43 (m, 6H), 3.00–2.86
(m, 2H), 2.09–1.94 (m, 2H), 1.94–1.67 (m, 2H), 1.48 (t, J = 3.2 Hz,
1H), 1.46–1.18 (m, 2H), 1.46 (s, 9H). 13C NMR (101 MHz, CDCl3) d
157.2, 137.9, 128.4, 127.7, 127.7, 78.5, 73.50, 70.9, 68.3, 50.62,
39.7, 38.8, 35.9, 32.1, 30.5, 29.4, 24.7. ESI-HRMS [C21H32N2O3+H]+:
361.24890 found, 361.24857 calculated.
4.2.20.8. 4-Chlorophenyl (1R,4aS,8aR)-1-((benzyloxy)methyl)hexahy-
dro-1H-pyrano[3,4-c]pyridine-7(3H)-carboxylate (15h). Colourless
liquid (25 mg, 89%), 1H NMR (400 MHz, CDCl3) d 7.29 (d,
J = 5.6 Hz, 7H), 7.03 (d, J = 8.9 Hz, 2H), 4.62 (d, J = 12.0 Hz, 1H),
4.51 (d, J = 12.0 Hz, 1H), 4.11–3.99 (m, 3H), 3.67 (bs, 1H), 3.63–
3.41 (m, 3H), 3.22–2.97 (m, 2H), 2.10–2.02 (m, 2H), 2.00–1.80
(m, 2H), 1.56 (d, J = 13.7 Hz, 1H), 1.30 (m, 1H). 13C NMR
(101 MHz, CDCl3) d 153.5, 149.9, 137.8, 130.5, 129.5, 129.2,
128.37, 127.9, 127.7, 123.2, 123.1, 78.6, 78.0, 77.3, 73.6, 70.8,
70.3, 68.3, 39.8, 39.5, 36.3, 32.1 30.8, 30.3, 24.7. ESI-HRMS [C23H26-
ClNO4+H]+: 416.16234 found, 416.16231 calculated.
4.2.20.9. (1R,4aS,8aR)-1-((Benzyloxy)methyl)-7-tosyloctahydro-1H-
pyrano[3,4-c]pyridine (15i). Colourless liquid (23 mg, 82%), 1H
NMR (400 MHz, CDCl3) d 7.62 (d, J = 8.2 Hz, 2H), 7.45–7.23 (m,
7H), 4.65 (d, J = 12.0 Hz, 1H), 4.52 (d, J = 12.0 Hz, 1H), 3.98 (dd,
J = 11.4, 4.5 Hz, 1H), 3.70–3.36 (m, 6H), 2.53 (t, J = 11.7 Hz, 1H),
2.44 (s, 3H), 2.38 (td, J = 12.4, 2.5 Hz, 1H), 2.03–1.87 (m, 3H), 1.69
(dd, J = 16.6, 12.6, 5.0 Hz, 1H), 1.53 (d, J = 11.8 Hz, 1H), 1.10 (d,
J = 13.3 Hz, 1H). 13C NMR (101 MHz, CDCl3) d 143.4, 137.7, 133.2,
129.7, 128.4, 127.9, 127.7, 127.5, 78.3, 73.6, 70.7, 68.3, 41.1, 36.2,
31.3, 30.0, 24.3, 21.5. ESI-HRMS [C23H29NO4S+H]+: 416.18888
found, 416.18901 calculated.
4.2.20.10. Isopropyl (1S,4aS,8aR)-1-((benzyloxy)methyl)hexahydro-
1H-pyrano[3,4-c]pyridine-7(3H)-carboxylate (16a). Colourless liq-
uid, (17.5 mg, 75%), 1H NMR (400 MHz, CDCl3) d 7.43–7.20 (m,
5H), 4.97–4.80 (m, 1H), 4.73 (d, J = 27.8 Hz, 1H), 4.48 (s, 1H), 4.29
(s, 2H), 3.85–3.56 (m, 5H), 2.75 (dd, J = 14.2, 2.8 Hz, 2H), 2.01 (s,
3H), 1.41 (dd, J = 17.6, 7.6 Hz, 1H), 1.34–0.98 (m, 8H). 13C NMR
(101 MHz, CDCl3) d 154.8, 128.3, 127.7, 127.6, 76.7, 73.6, 73.1,
68.4, 63.1, 45.4, 44.0, 35.2, 31.9, 31.0, 29.7, 25.5, 22.2, 22.1. ESI-
HRMS [C20H29NO4+H]+: 348.21699 found, 348.21693 calculated.
4.2.20.11. (1S,4aS,8aR)-7-(Mesitylsulfonyl)-1-(phenoxymethyl)oc-
tahydro-1H-pyrano[3,4-c]pyridine (16b). Colourless liquid,
(22.4 mg, 80%), 1H NMR (400 MHz, CDCl3) d 7.40–7.15 (m, 5H),
6.90 (s, 2H), 4.43 (d, J = 12.3 Hz, 1H), 4.20 (d, J = 12.3 Hz, 1H),
3.89–3.72 (m, 2H), 3.71–3.49 (m, 2H), 3.27 (dd, J = 12.9, 1.8 Hz,
1H), 3.23–3.14 (m, 1H), 2.90–2.67 (m, 3H), 2.57 (s, 6H), 2.27 (s,
3H), 2.16–1.84 (m, 4H), 1.51 (d, J = 12.9 Hz, 1H), 1.39 (d,
J = 13.0 Hz, 1H). 13C NMR (101 MHz, CDCl3) d 142.6, 140.5, 138.1,
131.8, 131.3, 128.3, 127.5, 127.5, 73.4, 73.11, 70.1, 63.2, 46.5,
43.9, 34.6, 31.5, 30.7, 24.9, 22.8, 20.9. ESI-HRMS [C25H33NO4S
+H]+: 444.22027 found, 444.22031 calculated.
4.2.20.12. ((1S,4aS,8aR)-1-(Phenoxymethyl)hexahydro-1H-pyrano
[3,4-c]pyridin-7(3H)-yl)(phenyl) methanone (16c). Colourless liquid,
(19 mg, 78%), colourless liquid 1H NMR (400 MHz, CDCl3) d 7.64–
7.08 (m, 10H), 4.66–4.15 (m, 3H), 4.05–3.39 (m, 5H), 3.30–2.79(m, 3H), 2.34–1.68 (m, 4H), 1.48 (d, J = 7.0 Hz, 2H). 13C NMR
(101 MHz, CDCl3) d 170.2, 138.3, 135.9, 129.6, 128.4, 128.3,
127.7, 127.5, 126.8, 73.5, 71.2, 62.9, 47.8, 43.9, 35.5, 31.9, 30.5,
29.7, 26.4. ESI-HRMS [C23H27NO3+H]+: 366.20667 found,
366.20637 calculated.
4.2.20.13. 4-Chlorophenyl (1S,4aS,8aR)-1-((benzyloxy)methyl)hex-
ahydro-1H-pyrano[3,4-c]pyridine-7(3H)-carboxylate (16d). Colour-
less liquid, (22.4 mg, 80%), 1H NMR (400 MHz, CDCl3) d 7.45–7.13
(m, 7H), 7.03 (d, J = 8.1 Hz, 1H), 6.89 (d, J = 8.5 Hz, 1H), 4.63 (t,
J = 12.4 Hz, 1H), 4.47 (bd, J = 12.2 Hz, 1H), 4.26 (t, J = 13.5 Hz, 1H),
4.20–4.04 (m, 1H), 3.94–3.59 (m, 5H), 3.13–2.76 (m, 2H), 2.09–
1.98 (m, 4H), 1.44 (d, J = 12.3 Hz, 2H). 13C NMR (101 MHz, CDCl3)
d 153.1, 149.6, 138.3, 137.9, 130.5, 129.2, 128.3, 127.85, 127.7,
127.5, 123.0, 73.6, 73.1, 71.1, 70.6, 63.1, 46.2, 45.9, 44.8, 44.5,
35.4, 35.2, 31.7, 30.8, 30.7, 25.8. ESI-HRMS [C23H26ClNO4+H]+:
416.16234 found, 416.16231 calculated.
4.2.20.14. (1S,4aS,8aR)-1-((Benzyloxy)methyl)-N-(tert-butyl)hexahy-
dro-1H-pyrano[3,4-c]pyridine-7(3H)-carboxamide (16e). Colourless
liquid, (20 mg, 82%), 1H NMR (400 MHz, CDCl3) d 7.44–7.20 (m,
5H), 4.66 (d, J = 12.5 Hz, 1H), 4.61–4.45 (m, 2H), 4.01 (d,
J = 12.8 Hz, 1H), 3.89 (d, J = 14.0 Hz, 1H), 3.83–3.51 (m, 5H), 2.79
(dd, J = 14.1, 3.4 Hz, 1H), 2.71 (t, J = 12.0 Hz, 1H), 2.08–1.82 (m,
4H), 1.51–1.33 (m, 1H), 1.28 (s, 9H). 13C NMR (101 MHz, CDCl3) d
157.0, 138.0, 128.4, 127.7, 127.7, 73.4, 72.4, 62.8, 50.4, 46.3,
43.85, 37.3, 32.1, 30.8, 29.5, 25.7. ESI-HRMS [C21H32N2O3+H]+:
361.24899 found, 361.24857 calculated.
4.2.20.15. (1S,4aS,8aR)-1-((benzyloxy)methyl)-7-tosyloctahydro-1H-
pyrano[3,4-c]pyridine (16f). Colourless liquid, (21 mg, 75%), 1H
NMR (400 MHz, CDCl3) d 7.55 (d, J = 8.2 Hz, 2H), 7.44–7.23 (m,
7H), 4.69 (d, J = 12.3 Hz, 1H), 4.49 (d, J = 12.3 Hz, 1H), 3.88 (dd,
J = 6.6, 5.1 Hz, 1H), 3.84–3.72 (m, 3H), 3.70–3.63 (m, 2H), 3.53 (d,
J = 12.0 Hz, 1H), 2.43 (s, 3H), 2.33–2.01 (m, 4H), 2.00–1.86 (m,
1H), 1.86–1.74 (m, 1H), 1.64 (d, J = 8.4 Hz, 1H), 1.45 (dd, J = 17.4,
4.0 Hz, 1H). 13C NMR (101 MHz, CDCl3) d 143.4, 138.3, 132.8,
129.6, 128.3, 127.9, 127.6, 127.5, 73.4, 73.1, 69.7, 63.3, 48.0, 46.5,
34.5 31.1, 30.51, 25.1, 21.5. ESI-HRMS [C23H29NO4S+H]+:
416.18891 found, 416.18901 calculated.
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